Key result
Blockade of ICAM-1 with mAb RR1/1 during reperfusion significantly reduced infarct size and improved postischemic myocardial blood flow compared with vehicle and control mAb in a rabbit model.
Why the study?
Does a monoclonal antibody against ICAM-1 improve postischemic myocardial blood flow and reduce infarct size in an anesthetized rabbit model of coronary occlusion and reperfusion?
Does a monoclonal antibody against ICAM-1 improve postischemic myocardial blood flow and reduce infarct size in an anesthetized rabbit model of coronary occlusion and reperfusion?
Blockade of ICAM-1 during reperfusion reduces postischemic perfusion defects and attenuates myocardial necrosis in a rabbit model of ischemia-reperfusion.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for ICAM-1 blockade in reperfusion injury; human trials required before clinical translation.
Zhao et al. (1997) studied Myocardial infarction / ischemia-reperfusion injury. Monoclonal antibody (mAb RR1/1) against ICAM-1 vs. Isotype-matched control mAb (R3.1) or saline vehicle was evaluated on Postischemic myocardial blood flow and infarct size. Blockade of ICAM-1 with mAb RR1/1 during reperfusion significantly reduced infarct size and improved postischemic myocardial blood flow compared with vehicle and control mAb in a rabbit model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: